NBDC Research ID: hum0187.v2

 

SUMMARY

Aims: Impact of viral integration into the host genome on development of hepatocellular carcinoma

Methods: Virus capture sequencing (NGS), Exome (NGS), RNA-seq (NGS), DNA_methylation (Infinium450K)

Participants/Materials: hepatocellular carcinoma

 

Dataset IDType of DataCriteriaRelease Date
JGAS000194 NGS (Target Capture) Controlled-access (Type I) 2020/05/12
JGAS000233 NGS (Exome, RNA-seq), Methylation array Controlled-access (Type I) 2021/05/31

*Release Note

*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

 

MOLECULAR DATA

Target Capture

Participants/Materials

hepatocellular carcinoma (ICD10: C220): 243 cases

  tumor tissue: 243 samples

  non-tumor tissue: 59 samples

Targets Target Capture
Target Loci for Capture Methods Virus integration site (including viral genome sequences, viral-human fusion sequences, and nonspecific human genome sequences)
Platform Illumina [MiSeq]
Library Source gDNAs extracted from tumor and non-tumor tissues of hepatocellular carcinoma
Cell Lines -
Library Construction (kit name) Agilent SureSelect XT custom kit
Fragmentation Methods Ultrasonic fragmentation (Covaris)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 200 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000277
Total Data Volume 640 GB(fastq)
Comments (Policies) NBDC policy

 

Exome

Participants/Materials

hepatocellular carcinoma (ICD10: C220): 160 cases

  tumor tissue: 160 samples

  non-tumor tissue: 160 samples

Targets Exome
Target Loci for Capture Methods -
Platform Illumina [HiSeq 2500]
Library Source DNAs extracted from tumor and non-tumor tissues
Cell Lines -
Library Construction (kit name) SeqCap EZ HGSC VCRome2.1 design1 (42 Mb, NimbleGen), SureSelect Human All Exon Kit V4/V5 (Agilent Technologies)
Fragmentation Methods Ultrasonic fragmentation (Covaris S2)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 100 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000328
Total Data Volume 7 TB (fastq, bam)
Comments (Policies) NBDC policy

 

RNA-seq

Participants/Materials

hepatocellular carcinoma (ICD10: C220): 160 cases

  tumor tissue: 160 samples

  non-tumor tissue: 31 samples

Targets RNA-seq
Target Loci for Capture Methods -
Platform Illumina [HiSeq 2500]
Library Source RNAs extracted from tumor and non-tumor tissues
Cell Lines -
Library Construction (kit name) TruSeq Stranded mRNA
Fragmentation Methods included in the above library construction kit
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 100 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000329
Total Data Volume 7 TB (fastq, bam)
Comments (Policies) NBDC policy

 

Methylation array

Participants/Materials

hepatocellular carcinoma (ICD10: C220): 160 cases

  tumor tissue: 160 samples

  non-tumor tissue: 28 samples

Targets Methylation array
Target Loci for Capture Methods -
Platform Illumina [Infinium Human Methylation 450K BeadChip]
Library Source DNAs extracted from tumor and non-tumor tissues
Cell Lines -
Library Construction (kit name) Infinium HumanMethylation450 BeadChip
Algorithms for Calculating Methylation-rate (software) Genome Studio
Filtering Methods -
Probe Number (after QC) 485,577 methylation sites
Japanese Genotype-phenotype Archive Dataset ID JGAD000330
Total Data Volume 7 TB (txt)
Comments (Policies) NBDC policy

 

DATA PROVIDER

Principal Investigator: Hiroyuki Aburatani

Affiliation: RCAST, the University of Tokyo

Project / Group Name: Genome Science laboratory

URL: https://www.genome.rcast.u-tokyo.ac.jp/en/research

Funds / Grants (Research Project Number):

NameTitleProject Number
Research on Development of New Medical Devices, Japan Agency for Medical Research and Development (AMED) Clinical trial of cancer diagnosis assisting machine based on the mass spectrometry and artificial intelligence: Towards improving the survival rate of hepatic tumor and reducing medical expense JP19hk0102049
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) Large-scale integrated genomic analysis of Japanese intractable and life-style related cancers as an international contribution to ICGC and WHO-lead collaborative researches towards precision cancer treatment and prevention JP19ck0106265
Research Program on Hepatitis, Japan Agency for Medical Research and Development (AMED) Study on the pathogenesis of metabolism-associated liver cancer including those associated with viral hepatitis JP19fk0210040
KAKENHI Grant-in-Aid for Scientific Research (C) Focal copy number alteration and its functional role in carcinogenesis: unmet needs in cancer genome analysis 17K07195

 

PUBLICATIONS

TitleDOIDataset ID
1 Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection doi: 10.1158/1078-0432.CCR-18-4041 JGAD000277
2 Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression doi: 10.1158/0008-5472.CAN-20-0225

JGAD000328

JGAD000329

JGAD000330

 

USRES (Controlled-access Data)

Principal InvestigatorAffiliationCountry/RegionResearch TitleData in Use (Dataset ID)Period of Data Use
Takashi Kohno Division of Genome Biology, National Cancer Center Research Institute Identification of genetic risk factors in AYA (Adolescence and Young Adult) cancer JGAD000277, JGAD000328, JGAD000329, JGAD000330 2021/11/29-2025/03/31
Jinyan Huang School of Medicine, Zhejiang University Comprehensive analysis of alternative splicing in malignant tumors JGAD000277 2022/03/07-2024/01/01
Michiaki Hamada Faculty of Science and Engineering, Waseda University Japan Construction of RNA-targeted Drug Discovery Database JGAD000329 2022/12/26-2025/03/31
Jian Cao Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey United States of America Analyzing oncovirus in NBDC tumor sequencing data JGAD000277,
JGAD000328,
JGAD000329,
JGAD000330
2023/01/11-2025/12/31